国医大师孙光荣:新时代如何传承发展好中医药

2017-12-23 朱蕗鋆 中国中医

党的十九大报告指出:实施“健康中国”战略,坚持中西医并重,传承发展中医药事业。那么,在中国发展已经步入新时代的大背景下,如何才能传承好、发展好中医药?

党的十九大报告指出:实施“健康中国”战略,坚持中西医并重,传承发展中医药事业。那么,在中国发展已经步入新时代的大背景下,如何才能传承好、发展好中医药?

方向:继承好 发展好 利用好

这对中医人提出了四点要求。一是要“增强民族自信”,不要崇洋媚外,不要数典忘祖,任何民族虚无主义都不利于中医药事业的发展。二是要“勇攀医学高峰”,不要徘徊观望,不要畏葸不前。中医药学是中国古代的智慧和经验的结晶,有的理论甚至是超前的、领先的,对医学高峰要有勇气攀登。三是要“深入发掘中医药宝库中的精华,充分发挥中医药的独特优势”。要重在继承,从中医药经典、老中医经验中吸取精华;重在发挥优势,不要西化、虚化、玄化、庸俗化,不要把具有特色优势的养生治未病、诊断、治疗、护理的理论和技术等老祖先的“传家宝”丢掉了。四是要“推进中医药现代化,推动中医药走向世界”,要在继承的基础上创新,要吸收现代科学技术,不要故步自封,不要墨守成规。总之,要对得起祖先,要做到“三好”——“切实把中医药这一祖先留给我们的宝贵财富继承好、发展好、利用好”。

继承好:中医药经典理论和老中医药专家学术经验,必须原原本本继承,这是学术进步和事业发展的基础。常言“基础不牢,地动山摇”,应当切忌用一些似是而非的所谓现代理论诠释、曲解、装饰中医药学,应当极力避免中医药理论的碎片化、空心化、边缘化。

发展好:自觉、自信、自主、自强,才能发展好。中医看病侧重于功能、动态、整体、宏观,西医看病侧重于结构、静态、局部、微观,各有各的特色和优势。中医如果模仿、套用西医的学术规范和标准,就势必弱化自身的特色优势,就不能很好地发挥在治未病中的主导作用、在治疗重大疾病中的协同作用、在康复治疗中的核心作用。我们必须自主研发和制定中医的学术规范和标准。

利用好:中医药学既是具有中国特色的医药学,更是包含中华文化元素的宝库,可以多层次、宽领域、广覆盖得加以利用。既可用以救死扶伤,又可用以养生防病;既可用以美容健身,又可用以养老长寿;既可用以健康旅游,又可用以扶贫脱困;既可用以传道授业解惑,又可用以科研开发;既可用以新兴产业,又可用以生态建设;既可用以文化传播,又可用以国际交流等等。

方针:坚持中西医并重,传承发展中医药事业

党的十九大报告突出建设健康中国的方针重点是:“坚持中西医并重,传承发展中医药事业”。

前面一句是针对现状而言。因为,“中西医并重”虽然提出多年了,但由于多种因素的制约,实际现状是并没有达到“并重”,无论在体系建设、机构规模、资金投入、人才培养、服务范围、服务层级等各个方面,都是西医为主、中医为辅。所以,首先必须真正做到“中西医并重”,而且要求“坚持”,也就是不能一时“并重”、一时又不“并重”;在这方面“并重”,在另一方面又不“并重”,而是必须一视同仁、平等对待。我们再回头看,进一步分析,就清晰地看到对中医的历史欠账太久、太多。正因如此,现阶段在政策制定、资金投入等方面就需要给予中医药必要的倾斜,这也就是中医药法颁布实施和国务院连续发布相关发展中医药若干重要文件的重要原因之一。

后面一句是针对未来而言。因为,中医药是国产的,从保有中华文化基因、凸显中医药特色优势、充分利用生态资源、构建简验便廉医疗保健体系、保障人民健康等各方面而言,国家都需要传承发展中医药事业。

我们既要尊重、学习、借鉴西医,在认识上做到“中西医并重”,更要自重、自信、自立、自强,“传承发展中医药事业”,用行动和效果证明“中西医并重”。

原则:创造性转化创新性发展

中医药应如何发展才能成为具有中国特色的新时代医药学?去年举行的全国卫生与健康大会强调,“要努力实现中医药健康养生文化的创造性转化、创新性发展”。这就确立了中医药事业发展的基本原则。

创造性转化:动力是“创造”,目的是“转化”,以期适应新时代的新要求。中医药的创造性转化的主要范畴:一是服务精神的转化,实现“大医精诚”传统精神对现代医疗服务行为的灌注,建立中医的《医师规》,以强化中医执业人员的自律和人民群众对恢复中医人文关怀传统的需求;二是服务理念的转化,实现“以疾病治疗为中心”向“以健康促进为中心”的重大转变,以适应新医改“战略前移”、“重心下移”的需求;三是服务模式的转化,由医院单向服务模式向共建共享服务模式转变,以适应“生长壮老已”全周期、广覆盖的养生防病、治病康复的全民健康需求;四是服务措施的转化,实现以内服汤剂为主向内治与外治相结合的口服、针推、药浴、导引等综合治疗转变,以适应对中医优势病种防治的需求,减少创伤、降低毒副作用,彰显中医药的特色优势。

创新性发展:动力是“创新”,目的是“发展”,以符合新时代的新目标。中医药创新性发展的主要范畴有五个。一是中医药理论创新,在继承经典理论的基础上,结合当代人类生存与生活的社会状况、生态环境、生活方式、病种演变等,基于“天人合一”、“形神合一”的原理创新中医药辨证论治理论和规范辨治程式。二是中医药技术创新,在望闻问切的传统诊断技术和汤膏丹丸散酒的传统治疗手段的基础上,结合现代科学技术,创新诊断方式和治疗手段。三是中医药人才培养模式创新,在以学校教育为主的基础上,尊重中医人才成长的规律,建立中医人才评价标准,结合现代信息技术,针对“准入”后的执业人员创新以师承+研修为主、不同层级的中医药人才培养模式。四是中医药科学研究模式创新,尊重中医以理论指导和临床实践积累为基础的科研传统,建立中医药科研成果评价标准,联合各界专业力量,结合大数据、云计算等现代信息技术,创新中医药科学研究模式;五是中医药文化传播方式创新,在成功开展“中医中药中国行”的基础上,培训专业队伍,搭建专门平台,加强基地建设,联合传统和新兴媒体,以基层、农村、社区、单位和一带一路沿线为主要阵地,创新中医药文化传播模式,不断增强中医药在中华文化传承领域和在全球传统医药领域的引领地位。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1675564, encodeId=12b116e55648a, content=<a href='/topic/show?id=8e7d258696c' target=_blank style='color:#2F92EE;'>#传承#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25869, encryptionId=8e7d258696c, topicName=传承)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85d827261473, createdName=lishizhe, createdTime=Wed Mar 14 10:02:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978073, encodeId=225919e807345, content=<a href='/topic/show?id=5bca258e611' target=_blank style='color:#2F92EE;'>#传承发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25876, encryptionId=5bca258e611, topicName=传承发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Sat Jun 16 10:02:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409252, encodeId=674414092523e, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Mon Dec 25 00:02:00 CST 2017, time=2017-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582640, encodeId=ae8a158264052, content=<a href='/topic/show?id=36455839121' target=_blank style='color:#2F92EE;'>#新时代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58391, encryptionId=36455839121, topicName=新时代)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Dec 25 00:02:00 CST 2017, time=2017-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=271809, encodeId=44c92e180904, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=7dcf1938111, createdName=1e0e5a1fm42(暂无匿称), createdTime=Sat Dec 23 11:19:28 CST 2017, time=2017-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=271765, encodeId=7df42e176587, content=学习了.好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Dec 23 09:09:23 CST 2017, time=2017-12-23, status=1, ipAttribution=)]
    2018-03-14 lishizhe
  2. [GetPortalCommentsPageByObjectIdResponse(id=1675564, encodeId=12b116e55648a, content=<a href='/topic/show?id=8e7d258696c' target=_blank style='color:#2F92EE;'>#传承#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25869, encryptionId=8e7d258696c, topicName=传承)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85d827261473, createdName=lishizhe, createdTime=Wed Mar 14 10:02:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978073, encodeId=225919e807345, content=<a href='/topic/show?id=5bca258e611' target=_blank style='color:#2F92EE;'>#传承发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25876, encryptionId=5bca258e611, topicName=传承发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Sat Jun 16 10:02:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409252, encodeId=674414092523e, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Mon Dec 25 00:02:00 CST 2017, time=2017-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582640, encodeId=ae8a158264052, content=<a href='/topic/show?id=36455839121' target=_blank style='color:#2F92EE;'>#新时代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58391, encryptionId=36455839121, topicName=新时代)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Dec 25 00:02:00 CST 2017, time=2017-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=271809, encodeId=44c92e180904, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=7dcf1938111, createdName=1e0e5a1fm42(暂无匿称), createdTime=Sat Dec 23 11:19:28 CST 2017, time=2017-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=271765, encodeId=7df42e176587, content=学习了.好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Dec 23 09:09:23 CST 2017, time=2017-12-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1675564, encodeId=12b116e55648a, content=<a href='/topic/show?id=8e7d258696c' target=_blank style='color:#2F92EE;'>#传承#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25869, encryptionId=8e7d258696c, topicName=传承)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85d827261473, createdName=lishizhe, createdTime=Wed Mar 14 10:02:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978073, encodeId=225919e807345, content=<a href='/topic/show?id=5bca258e611' target=_blank style='color:#2F92EE;'>#传承发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25876, encryptionId=5bca258e611, topicName=传承发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Sat Jun 16 10:02:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409252, encodeId=674414092523e, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Mon Dec 25 00:02:00 CST 2017, time=2017-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582640, encodeId=ae8a158264052, content=<a href='/topic/show?id=36455839121' target=_blank style='color:#2F92EE;'>#新时代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58391, encryptionId=36455839121, topicName=新时代)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Dec 25 00:02:00 CST 2017, time=2017-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=271809, encodeId=44c92e180904, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=7dcf1938111, createdName=1e0e5a1fm42(暂无匿称), createdTime=Sat Dec 23 11:19:28 CST 2017, time=2017-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=271765, encodeId=7df42e176587, content=学习了.好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Dec 23 09:09:23 CST 2017, time=2017-12-23, status=1, ipAttribution=)]
    2017-12-25 cathymary
  4. [GetPortalCommentsPageByObjectIdResponse(id=1675564, encodeId=12b116e55648a, content=<a href='/topic/show?id=8e7d258696c' target=_blank style='color:#2F92EE;'>#传承#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25869, encryptionId=8e7d258696c, topicName=传承)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85d827261473, createdName=lishizhe, createdTime=Wed Mar 14 10:02:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978073, encodeId=225919e807345, content=<a href='/topic/show?id=5bca258e611' target=_blank style='color:#2F92EE;'>#传承发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25876, encryptionId=5bca258e611, topicName=传承发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Sat Jun 16 10:02:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409252, encodeId=674414092523e, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Mon Dec 25 00:02:00 CST 2017, time=2017-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582640, encodeId=ae8a158264052, content=<a href='/topic/show?id=36455839121' target=_blank style='color:#2F92EE;'>#新时代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58391, encryptionId=36455839121, topicName=新时代)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Dec 25 00:02:00 CST 2017, time=2017-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=271809, encodeId=44c92e180904, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=7dcf1938111, createdName=1e0e5a1fm42(暂无匿称), createdTime=Sat Dec 23 11:19:28 CST 2017, time=2017-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=271765, encodeId=7df42e176587, content=学习了.好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Dec 23 09:09:23 CST 2017, time=2017-12-23, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1675564, encodeId=12b116e55648a, content=<a href='/topic/show?id=8e7d258696c' target=_blank style='color:#2F92EE;'>#传承#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25869, encryptionId=8e7d258696c, topicName=传承)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85d827261473, createdName=lishizhe, createdTime=Wed Mar 14 10:02:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978073, encodeId=225919e807345, content=<a href='/topic/show?id=5bca258e611' target=_blank style='color:#2F92EE;'>#传承发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25876, encryptionId=5bca258e611, topicName=传承发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Sat Jun 16 10:02:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409252, encodeId=674414092523e, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Mon Dec 25 00:02:00 CST 2017, time=2017-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582640, encodeId=ae8a158264052, content=<a href='/topic/show?id=36455839121' target=_blank style='color:#2F92EE;'>#新时代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58391, encryptionId=36455839121, topicName=新时代)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Dec 25 00:02:00 CST 2017, time=2017-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=271809, encodeId=44c92e180904, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=7dcf1938111, createdName=1e0e5a1fm42(暂无匿称), createdTime=Sat Dec 23 11:19:28 CST 2017, time=2017-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=271765, encodeId=7df42e176587, content=学习了.好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Dec 23 09:09:23 CST 2017, time=2017-12-23, status=1, ipAttribution=)]
    2017-12-23 1e0e5a1fm42(暂无匿称)

    henhao

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1675564, encodeId=12b116e55648a, content=<a href='/topic/show?id=8e7d258696c' target=_blank style='color:#2F92EE;'>#传承#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25869, encryptionId=8e7d258696c, topicName=传承)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85d827261473, createdName=lishizhe, createdTime=Wed Mar 14 10:02:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978073, encodeId=225919e807345, content=<a href='/topic/show?id=5bca258e611' target=_blank style='color:#2F92EE;'>#传承发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25876, encryptionId=5bca258e611, topicName=传承发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Sat Jun 16 10:02:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409252, encodeId=674414092523e, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Mon Dec 25 00:02:00 CST 2017, time=2017-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582640, encodeId=ae8a158264052, content=<a href='/topic/show?id=36455839121' target=_blank style='color:#2F92EE;'>#新时代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58391, encryptionId=36455839121, topicName=新时代)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Dec 25 00:02:00 CST 2017, time=2017-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=271809, encodeId=44c92e180904, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=7dcf1938111, createdName=1e0e5a1fm42(暂无匿称), createdTime=Sat Dec 23 11:19:28 CST 2017, time=2017-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=271765, encodeId=7df42e176587, content=学习了.好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Dec 23 09:09:23 CST 2017, time=2017-12-23, status=1, ipAttribution=)]
    2017-12-23 1ddf0692m34(暂无匿称)

    学习了.好文章

    0

相关资讯

积极开创新时代医改宣传新局面

12月10日,由《中国卫生》杂志社、《健康报》社主办的2017中国医改传播高峰论坛在京召开,主论坛主题为“迈进医改新时代”。

[深度] 健康领域新矛盾需要新对策

党的十九大,是在全面建成小康社会决胜阶段、中国特色社会主义进入新时代这一关键时期召开的重要大会。大会提出我国社会主要矛盾已经转化为人民日益增长的美好生活需要和不平衡不充分的发展之间的矛盾这一重要论断,对各个领域的发展均具有指导意义。

魏子柠:中国进入新时代 医改重在供给侧

党的十九大作出了中国特色社会主义进入新时代,我国社会主要矛盾已经转化为人民日益增长的美好生活需要和不平衡不充分发展之间的矛盾的两个重大判断。还提出,要继续深化供给侧结构性改革,加快发展现代服务业,优化存量资源配置,扩大优质资源供给,实现供需动态平衡;要实施健康中国战略,深化医药卫生体制改革,为人民群众提供全方位全周期的健康服务。这两个重大判断,明确了我国发展的新的历史方位,为我们深刻把握当代中

新时代 公立医院改革再出发

党的十九大指出,我国社会主要矛盾已经转化为人民日益增长的美好生活需要和不平衡不充分的发展之间的矛盾。就医疗卫生领域而言,解决新矛盾就要从服务供给侧发力,努力回应人民群众多层次、多样化的健康需求。

国家中医药局:推动新时代中医药发展

12月11~13日,国家中医药管理局处级以上领导干部学习贯彻党的十九大精神集中轮训暨中医药管理干部提升治理能力培训班在京举行。国家卫生计生委副主任,国家中医药管理局党组书记、局长王国强在培训总结时强调,要坚持用习近平新时代中国特色社会主义思想武装头脑,推动新时代中医药振兴发展。